Ciprofloxacin for Prevention of BK Infection

Inclusion Criteria: * Male or female subjects over the age of 18 years * Recipients of a primary or repeat renal allograft either alone (from a deceased or living donor) or as a dual-kidney transplant * Signed informed consent form prior to any research assessment Exclusion Criteria: * Patients with known severe allergy to ciprofloxacin * History of tendon rupture or tendinitis * Use of antiarrythmic drugs known to prolong the QT interval such as class IA antiarrhythmic drugs (e.g. quinidine, procainamide, disopyramide), class III antiarrhythmic drugs (e.g. amiodarone, sotalol) * Patients with history of previous non-renal transplantation * Recipients administered rituximab within one year prior to transplantation, or recipients expected to receive rituximab as part of desensitization strategy or for the presence of historical donor specific antibodies * QTc interval interval of greater than 500 msec on admission or post-operative EKG * BK nephropathy with previous transplant * BK viremia on admission * Any condition present during the initial transplant hospitalization that in the investigator's judgment would increase the risk associated with participation in the study